ArticleTherapeutic advances in medical oncology2022

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.

Maria-Pilar Barretina-Ginesta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.